In this ongoing phase I trial being conducted by the NHLBI at the NIH Clinical Center, escalating doses of autologous CD8+ T cells transduced to express a TCR recognizing the CT-RCC HERV-E antigen are infused into HLA-A11 positive patients with metastatic ccRCC in a dose escalating fashion (NCT03354390). This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.